Literature DB >> 11131300

Histamine up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils.

F J Dasí1, J L Ortiz, J Cortijo, E J Morcillo.   

Abstract

OBJECTIVE: To investigate whether histamine produces up-regulation of phosphodiesterase (PDE) activity with functional consequences in human peripheral blood neutrophils.
METHODS: PDE activity was studied by a radioisotopic method following anion-exchange chromatography. Reverse transcriptase-polymerase chain reaction (RT-PCR) was used for detection of mRNA transcripts of PDE4 subtypes. Cyclic AMP (cAMP) levels were measured by enzyme-immunoassay, and superoxide generation by cytochrome c reduction. TREATMENT: Neutrophils were incubated for 4 h with histamine (1 microM).
RESULTS: PDE4 was the only isoenzyme activity increased in treated neutrophils. Kinetic analysis showed a approximately 1.5-fold increase in Vmax without alteration of Km values. cAMP content in treated cells was higher than resting values (0.52+/-0.07 vs. 2.75+/-0.31 pmol/10(6) cells). RT-PCR showed increased expression of mRNA transcripts for PDE4B in histamine-treated cells. Functionally, up-regulation of PDE4 reduced the inhibition by prostaglandin E2 of zymosan-induced superoxide generation.
CONCLUSION: Histamine up-regulates PDE4 activity and produces heterologous desensitisation of human neutrophils.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11131300     DOI: 10.1007/s000110050637

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  1 in total

1.  Effect of two phenanthrene alkaloids on angiotensin II-induced leukocyte-endothelial cell interactions in vivo.

Authors:  Rossana Estellés; Javier López-Martín; Lara Milian; José-Enrique O'Connor; Magdalena Martínez-Losa; Miguel Cerdá-Nicolás; Edet M Anam; María Dolores Ivorra; Andrew C Issekutz; Julio Cortijo; Esteban J Morcillo; Maria Amparo Blázquez; Maria-Jesús Sanz
Journal:  Br J Pharmacol       Date:  2003-10-14       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.